Risk Factors for Graft-versus-Host Disease in Haploidentical Hematopoietic Cell Transplantation Using Post-Transplant Cyclophosphamide.

Adult Cyclophosphamide / therapeutic use Graft vs Host Disease Hematopoietic Stem Cell Transplantation / adverse effects Humans Risk Factors Transplantation Conditioning

Journal

Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
ISSN: 1523-6536
Titre abrégé: Biol Blood Marrow Transplant
Pays: United States
ID NLM: 9600628

Informations de publication

Date de publication:
08 2020
Historique:
received: 08 01 2020
revised: 31 03 2020
accepted: 04 05 2020
pubmed: 21 5 2020
medline: 24 6 2021
entrez: 21 5 2020
Statut: ppublish

Résumé

Post-transplant cyclophosphamide (PTCy) has significantly increased the successful use of haploidentical donors with a relatively low incidence of graft-versus-host disease (GVHD). Given its increasing use, we sought to determine risk factors for GVHD after haploidentical hematopoietic cell transplantation (haplo-HCT) using PTCy. Data from the Center for International Blood and Marrow Transplant Research on adult patients with acute myeloid leukemia, acute lymphoblastic leukemia, myelodysplastic syndrome, or chronic myeloid leukemia who underwent PTCy-based haplo-HCT (2013 to 2016) were analyzed and categorized into 4 groups based on myeloablative (MA) or reduced-intensity conditioning (RIC) and bone marrow (BM) or peripheral blood (PB) graft source. In total, 646 patients were identified (MA-BM = 79, MA-PB = 183, RIC-BM = 192, RIC-PB = 192). The incidence of grade 2 to 4 acute GVHD at 6 months was highest in MA-PB (44%), followed by RIC-PB (36%), MA-BM (36%), and RIC-BM (30%) (P = .002). The incidence of chronic GVHD at 1 year was 40%, 34%, 24%, and 20%, respectively (P < .001). In multivariable analysis, there was no impact of stem cell source or conditioning regimen on grade 2 to 4 acute GVHD; however, older donor age (30 to 49 versus <29 years) was significantly associated with higher rates of grade 2 to 4 acute GVHD (hazard ratio [HR], 1.53; 95% confidence interval [CI], 1.11 to 2.12; P = .01). In contrast, PB compared to BM as a stem cell source was a significant risk factor for the development of chronic GVHD (HR, 1.70; 95% CI, 1.11 to 2.62; P = .01) in the RIC setting. There were no differences in relapse or overall survival between groups. Donor age and graft source are risk factors for acute and chronic GVHD, respectively, after PTCy-based haplo-HCT. Our results indicate that in RIC haplo-HCT, the risk of chronic GVHD is higher with PB stem cells, without any difference in relapse or overall survival.

Identifiants

DOI: 10.1016/j.bbmt.2020.05.001 PMID: 32434056 PMC: PMC7391266
pubmed: 32434056
pii: S1083-8791(20)30286-X
doi: 10.1016/j.bbmt.2020.05.001
pmc: PMC7391266
mid: NIHMS1604025
pii:
doi:

Substances chimiques

Cyclophosphamide 8N3DW7272P

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, U.S. Gov't, Non-P.H.S. Research Support, U.S. Gov't, P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

1459-1468

Subventions

Organisme : NIAID NIH HHS
ID : U01 AI126612
Pays : United States
Organisme : NHLBI NIH HHS
ID : R21 HL140314
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA231141
Pays : United States
Organisme : NHLBI NIH HHS
ID : U01 HL128568
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL129472
Pays : United States
Organisme : NCI NIH HHS
ID : P01 CA111412
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL131731
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL126589
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA152108
Pays : United States
Organisme : NCI NIH HHS
ID : U24 CA076518
Pays : United States
Organisme : NHLBI NIH HHS
ID : U24 HL138660
Pays : United States

Informations de copyright

Copyright © 2020 American Society for Transplantation and Cellular Therapy. All rights reserved.

Références

Blood. 2012 Jan 5;119(1):296-307
pubmed: 22010102
N Engl J Med. 2017 Dec 28;377(26):2565-2579
pubmed: 29281578
Blood. 2002 Jul 15;100(2):415-9
pubmed: 12091330
Blood. 2015 Feb 19;125(8):1333-8
pubmed: 25593335
Biol Blood Marrow Transplant. 2016 Jan;22(1):125-33
pubmed: 26359881
Blood. 2014 Jun 5;123(23):3664-71
pubmed: 24744269
Biol Blood Marrow Transplant. 2014 Dec;20(12):1975-81
pubmed: 25263628
Blood. 2016 Feb 18;127(7):938-47
pubmed: 26670632
Am J Med. 1980 Aug;69(2):204-17
pubmed: 6996481
Biol Blood Marrow Transplant. 2016 Sep;22(9):1696-1701
pubmed: 27223108
Biol Blood Marrow Transplant. 2012 Aug;18(8):1150-63
pubmed: 22510384
Bone Marrow Transplant. 1995 Jun;15(6):825-8
pubmed: 7581076
Biol Blood Marrow Transplant. 2016 Jan;22(1):119-24
pubmed: 26341397
N Engl J Med. 2016 Jan 7;374(1):43-53
pubmed: 26735993
Blood. 2015 May 7;125(19):3024-31
pubmed: 25814532
Blood. 2006 Dec 15;108(13):4288-90
pubmed: 16946302
Blood. 2011 Jul 14;118(2):282-8
pubmed: 21527516
Blood. 2005 Oct 15;106(8):2912-9
pubmed: 15994282
J Clin Oncol. 2015 Oct 1;33(28):3152-61
pubmed: 26261255
Bone Marrow Transplant. 2016 Dec;51(12):1599-1601
pubmed: 27526284
Biol Blood Marrow Transplant. 2018 Feb;24(2):343-352
pubmed: 29055682
Biol Blood Marrow Transplant. 2014 May;20(5):724-9
pubmed: 24530426
Am J Hematol. 2018 Feb;93(2):246-253
pubmed: 29114918
J Clin Oncol. 2016 Sep 10;34(26):3141-9
pubmed: 27269951
Biol Blood Marrow Transplant. 2009 Dec;15(12):1628-33
pubmed: 19896087
Biol Blood Marrow Transplant. 2019 Oct;25(10):2054-2060
pubmed: 31173900
Cancer. 2016 Nov 15;122(21):3316-3326
pubmed: 27404668
J Clin Oncol. 2013 Apr 1;31(10):1310-6
pubmed: 23423745
N Engl J Med. 2012 Oct 18;367(16):1487-96
pubmed: 23075175
Biol Blood Marrow Transplant. 2014 Oct;20(10):1573-9
pubmed: 24910379
J Clin Oncol. 2017 Sep 10;35(26):3002-3009
pubmed: 28644773
Blood. 2015 Aug 20;126(8):1033-40
pubmed: 26130705
Biol Blood Marrow Transplant. 2008 Jun;14(6):641-50
pubmed: 18489989
Biol Blood Marrow Transplant. 2002;8(7):377-86
pubmed: 12171484
Biol Blood Marrow Transplant. 2015 Mar;21(3):389-401.e1
pubmed: 25529383
Biol Blood Marrow Transplant. 2008 Jul;14(7):748-58
pubmed: 18541193
N Engl J Med. 2001 Jan 18;344(3):175-81
pubmed: 11172139
Biol Blood Marrow Transplant. 2007 May;13(5):584-93
pubmed: 17448918
Bone Marrow Transplant. 2008 Aug;42 Suppl 1:S1-S2
pubmed: 18724277
Biol Blood Marrow Transplant. 2009 Mar;15(3):367-9
pubmed: 19203728
Blood. 2012 Jul 26;120(4):905-13
pubmed: 22709687
Biol Blood Marrow Transplant. 2012 Dec;18(12):1859-66
pubmed: 22863841

Auteurs

Annie Im (A)

University of Pittsburgh/UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania.

Armin Rashidi (A)

Division of Hematology, Oncology and Transplantation, Department of Medicine, University of Minnesota, Minneapolis, Minnesota.

Tao Wang (T)

Department of Medicine, Medical College of Wisconsin, CIBMTR® (Center for International Blood and Marrow Transplant Research), Milwaukee, Wisconsin; Division of Biostatistics, Institute for Health and Equity, Medical College of Wisconsin, Milwaukee, Wisconsin.

Michael Hemmer (M)

Department of Medicine, Medical College of Wisconsin, CIBMTR® (Center for International Blood and Marrow Transplant Research), Milwaukee, Wisconsin.

Margaret L MacMillan (ML)

Blood and Marrow Transplant Program, Department of Pediatrics, University of Minnesota, Minneapolis, Minnesota.

Joseph Pidala (J)

H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida.

Madan Jagasia (M)

Vanderbilt University Medical Center, Nashville, Tennessee.

Steven Pavletic (S)

Immune Deficiency Cellular Therapy Program, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland.

Navneet S Majhail (NS)

Blood & Marrow Transplant Program, Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio.

Daniel Weisdorf (D)

Division of Hematology, Oncology and Transplantation, Department of Medicine, University of Minnesota, Minneapolis, Minnesota.

Hisham Abdel-Azim (H)

(0)Division of Hematology, Oncology and Blood & Marrow Transplantation, Children's Hospital Los Angeles, University of Southern California Keck School of Medicine, Los Angeles, California.

Vaibhav Agrawal (V)

Division of Hematology-Oncology, Indiana University School of Medicine, Indianapolis, Indiana.

A Samer Al-Homsi (AS)

(2)New York University Langone Medical Center, New York, New York.

Mahmoud Aljurf (M)

(3)Department of Oncology, King Faisal Specialist Hospital Center & Research, Riyadh, Saudi Arabia.

Medhat Askar (M)

(4)Department of Pathology and Laboratory Medicine, Baylor University Medical Center, Dallas, Texas.

Jeffery J Auletta (JJ)

(5)Blood and Marrow Transplant Program and Host Defense Program, Divisions of Hematology/Oncology/Bone Marrow Transplant and Infectious Diseases, Nationwide Children's Hospital, Columbus, Ohio.

Asad Bashey (A)

(6)Blood and Marrow Transplant Program at Northside Hospital, Atlanta, Georgia.

Amer Beitinjaneh (A)

(7)Department of Hematology and Oncology, University of Miami, Miami, Florida.

Vijaya Raj Bhatt (VR)

(8)The Fred and Pamela Buffett Cancer Center, University of Nebraska Medical Center, Omaha, Nebraska.

Michael Byrne (M)

Vanderbilt University Medical Center, Nashville, Tennessee.

Jean-Yves Cahn (JY)

Department of Hematology, CHU Grenoble Alpes, Grenoble, France.

Mitchell Cairo (M)

(0)Division of Pediatric Hematology, Oncology and Stem Cell Transplantation, Department of Pediatrics, New York Medical College, Valhalla, New York.

Paul Castillo (P)

(1)UF Health Shands Children's Hospital, Gainesville, Florida.

Jan Cerny (J)

Division of Hematology/Oncology, Department of Medicine, University of Massachusetts Medical Center, Worcester, Massachusetts.

Saurabh Chhabra (S)

Department of Medicine, Medical College of Wisconsin, CIBMTR® (Center for International Blood and Marrow Transplant Research), Milwaukee, Wisconsin.

Hannah Choe (H)

(3)James Comprehensive Cancer Center, The Ohio State University Wexner Medical Center, Columbus, Ohio.

Stefan Ciurea (S)

(4)The University of Texas MD Anderson Cancer Center, Houston, Texas.

Andrew Daly (A)

(5)Tom Baker Cancer Center, Calgary, Alberta, Canada.

Miguel Angel Diaz Perez (MAD)

(6)Department of Hematology/Oncology, Hospital Infantil Universitario Nino Jesus, Madrid, Spain.

Nosha Farhadfar (N)

(7)Division of Hematology/Oncology, University of Florida College of Medicine, Gainesville, Florida.

Shahinaz M Gadalla (SM)

(8)Division of Cancer Epidemiology & Genetics, NIH-NCI Clinical Genetics Branch, Rockville, Maryland.

Robert Gale (R)

Hematology Research Centre, Division of Experimental Medicine, Department of Medicine, Imperial College London, London, United Kingdom.

Siddhartha Ganguly (S)

(0)Division of Hematological Malignancy and Cellular Therapeutics, University of Kansas Health System, Kansas City, Kansas.

Usama Gergis (U)

(1)Department of Medical Oncology, Thomas Jefferson University, Philadelphia, Pennsylvania.

Rabi Hanna (R)

(2)Cleveland Clinic Foundation, Cleveland, Ohio.

Peiman Hematti (P)

Division of Hematology/Oncology/Bone Marrow Transplantation, Department of Medicine, University of Wisconsin, Madison, Wisconsin.

Roger Herzig (R)

(4)University of Kentucky Chandler Medical Center, Louisville, Kentucky.

Gerhard C Hildebrandt (GC)

(5)Markey Cancer Center, University of Kentucky, Lexington, Kentucky.

Deepesh P Lad (DP)

(6)Department of Internal Medicine, Postgraduate Institute of Medical Education and Research, Chandigarh, India.

Catherine Lee (C)

(7)Utah Blood and Marrow Transplant Program at Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah.

Leslie Lehmann (L)

(8)Dana-Farber Cancer Institute/Boston Children's Hospital, Boston, Massachusetts.

Lazaros Lekakis (L)

(7)Department of Hematology and Oncology, University of Miami, Miami, Florida.

Rammurti T Kamble (RT)

Division of Hematology and Oncology, Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, Texas.

Mohamed A Kharfan-Dabaja (MA)

(0)Division of Hematology-Oncology, Blood and Marrow Transplantation Program, Mayo Clinic, Jacksonville, Florida.

Pooja Khandelwal (P)

(1)Division of Bone Marrow Transplant and Immune Deficiency, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio; (2)Department of Pediatrics, University of Cincinnati, Cincinnati, Ohio.

Rodrigo Martino (R)

(3)Divison of Clinical Hematology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.

Hemant S Murthy (HS)

(0)Division of Hematology-Oncology, Blood and Marrow Transplantation Program, Mayo Clinic, Jacksonville, Florida.

Taiga Nishihori (T)

Department of Blood & Marrow Transplant and Cellular Immunotherapy (BMT CI), Moffitt Cancer Center, Tampa, Florida.

Tracey A O'Brien (TA)

(5)Blood & Marrow Transplant Program, Kids Cancer Centre, Sydney Children's Hospital, Sydney, Australia.

Richard F Olsson (RF)

(6)Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden; (7)Centre for Clinical Research Sormland, Uppsala University, Uppsala, Sweden.

Sagar S Patel (SS)

(8)Blood and Marrow Transplant Program, University of Utah, Salt Lake City, Utah.

Miguel-Angel Perales (MA)

Adult Bone Marrow Transplant Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.

Tim Prestidge (T)

(0)Blood and Cancer Centre, Starship Children's Hospital, Auckland, New Zealand.

Muna Qayed (M)

(1)Department of Pediatrics, Emory University School of Medicine, Atlanta, Georgia.

Rizwan Romee (R)

(2)Dana Farber Cancer Institute, Boston, Massachusetts.

Hélène Schoemans (H)

(3)Department of Hematology, University Hospitals Leuven and KU Leuven, Leuven, Belgium.

Sachiko Seo (S)

(4)Department of Hematology and Oncology, Dokkyo Medical University, Tochigi, Japan.

Akshay Sharma (A)

Department of Bone Marrow Transplantation and Cellular Therapy, St. Jude Children's Research Hospital, Memphis, Tennessee.

Melhem Solh (M)

(6)The Blood and Marrow Transplant Group of Georgia, Northside Hospital, Atlanta, Georgia.

Roger Strair (R)

(7)Rutgers Cancer Institute of New Jersey, Rutgers University, Brunswick, New Jersey.

Takanori Teshima (T)

(8)Hokkaido University Hospital, Sapporo, Japan.

Alvaro Urbano-Ispizua (A)

Department of Hematology, Hospital Clinic, University of Barcelona, IDIBAPS, and Institute of Research Josep Carreras, Barcelona, Spain.

Marjolein Van der Poel (M)

(0)Maastricht University Medical Center, Maastricht, the Netherlands.

Ravi Vij (R)

(1)Division of Hematology and Oncology, Washington University School of Medicine, St. Louis, Missouri.

John L Wagner (JL)

(2)Department of Medical Oncology, Thomas Jefferson University, Philadelphia, Pennsylvania.

Basem William (B)

(3)Division of Hematology, The Ohio State University, Columbus, Ohio.

Baldeep Wirk (B)

(4)Bone Marrow Transplant Program, Penn State Cancer Institute, Hershey, Pennsylvania.

Jean A Yared (JA)

(5)Blood & Marrow Transplantation Program, Division of Hematology/Oncology, Department of Medicine, Greenebaum Comprehensive Cancer Center, University of Maryland, Baltimore, Maryland.

Steve R Spellman (SR)

Department of Medicine, Medical College of Wisconsin, CIBMTR® (Center for International Blood and Marrow Transplant Research), Milwaukee, Wisconsin.

Mukta Arora (M)

Division of Hematology, Oncology and Transplantation, Department of Medicine, University of Minnesota, Minneapolis, Minnesota.

Betty K Hamilton (BK)

Blood & Marrow Transplant Program, Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio. Electronic address: hamiltb2@ccf.org.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Risk Factors for Graft-versus-Host Disease in...
questionsmedicales.fr › Composés chimiques organiques › Composés organiques du phosphore › Phosphoramides › Moutardes phosphoramide › Cyclophosphamide › Risk Factors for Graft-versus-Host Disease in...
questionsmedicales.fr › Maladies du système immunitaire › Maladie du greffon contre l'hôte › Risk Factors for Graft-versus-Host Disease in...
questionsmedicales.fr › Procédures de chirurgie opératoire › Transplantation › Transplantation cellulaire › Transplantation de cellules souches › Transplantation de cellules souches hématopoïétiques › Risk Factors for Graft-versus-Host Disease in...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Risk Factors for Graft-versus-Host Disease in...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Statistiques comme sujet › Probabilité › Risque › Facteurs de risque › Risk Factors for Graft-versus-Host Disease in...
questionsmedicales.fr › Techniques d'investigation › Techniques immunologiques › Immunosuppression thérapeutique › Conditionnement pour greffe › Risk Factors for Graft-versus-Host Disease in...